Archives of Neuroscience

Published by: Kowsar

Serum Homocysteine Level and Lipid Profile in Migraine Patients Treated with Sodium Valproate

Shirin Shakiba 1 , Majid Ghafarpour 2 , Payam Sarraf 2 , Sakineh Ranji-Burachaloo 2 , Ali Shakiba 1 and Abbas Tafakhori 2 , *
Authors Information
1 Tehran University of Medical Sciences, Tehran, Iran
2 Neuroscience institute, Iranian Center of Neurological Research, Tehran, Iran
Article information
  • Archives of Neuroscience: 6 (1); e79504
  • Published Online: September 26, 2018
  • Article Type: Research Article
  • Received: May 21, 2018
  • Revised: August 16, 2018
  • Accepted: September 8, 2018
  • DOI: 10.5812/ans.79504

To Cite: Shakiba S, Ghafarpour M, Sarraf P, Ranji-Burachaloo S, Shakiba A, et al. Serum Homocysteine Level and Lipid Profile in Migraine Patients Treated with Sodium Valproate, Arch Neurosci. Online ahead of Print ; 6(1):e79504. doi: 10.5812/ans.79504.

Copyright © 2018, Archives of Neuroscience. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2. [PubMed: 23245607].
  • 2. Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, et al. Migraine and risk of cardiovascular disease in women: Prospective cohort study. BMJ. 2016;353. i2610. doi: 10.1136/bmj.i2610. [PubMed: 27247281]. [PubMed Central: PMC4887613].
  • 3. Tietjen GE. Migraine as a systemic disorder. Neurology. 2007;68(19):1555-6. doi: 10.1212/01.wnl.0000265415.18382.fb. [PubMed: 17485641].
  • 4. Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered arterial function in migraine of recent onset. Neurology. 2007;68(19):1563-70. doi: 10.1212/01.wnl.0000260964.28393.ed. [PubMed: 17460157].
  • 5. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ. 2009;339:b3914. doi: 10.1136/bmj.b3914. [PubMed: 19861375]. [PubMed Central: PMC2768778].
  • 6. Adelborg K, Szepligeti SK, Holland-Bill L, Ehrenstein V, Horvath-Puho E, Henderson VW, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96. doi: 10.1136/bmj.k96. [PubMed: 29386181]. [PubMed Central: PMC5791041].
  • 7. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6). CD010611. doi: 10.1002/14651858.CD010611. [PubMed: 23797677].
  • 8. Belcastro V, D'Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016. [PubMed: 24076030].
  • 9. Gorjipour F, Asadi Y, Osguei NK, Effatkhah M, Samadikuchaksaraei A. Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: A systematic review and meta-analysis. Iran Red Crescent Med J. 2013;15(3):249-53. doi: 10.5812/ircmj.9690. [PubMed: 23984007]. [PubMed Central: PMC3745756].
  • 10. Green MW, Giordano S, Jiang P, Jafari M, Smith TB. Effect of divalproex on metabolic parameters is dose related in migraine prophylaxis. Headache. 2005;45(8):1031-7. doi: 10.1111/j.1526-4610.2005.05184.x. [PubMed: 16109117].
  • 11. Headache Classification Committee of the International Headache Society (IHS). Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2013;33(9):629-808. doi: 10.1177/0333102413485658. [PubMed: 23771276].
  • 12. Eiris J, Novo-Rodriguez MI, Del Rio M, Meseguer P, Del Rio MC, Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res. 2000;41(1):1-7. [PubMed: 10924863].
  • 13. Chuang YC, Chuang HY, Lin TK, Chang CC, Lu CH, Chang WN, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53(1):120-8. doi: 10.1111/j.1528-1167.2011.03316.x. [PubMed: 22085257].
  • 14. Nikolaos T, Stylianos G, Chryssoula N, Irini P, Christos M, Dimitrios T, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit. 2004;10(4):MT50-2. [PubMed: 15039653].
  • 15. Abaci A, Saygi M, Yis U, Demir K, Dirik E, Bober E. Metabolic alterations during valproic acid treatment: A prospective study. Pediatr Neurol. 2009;41(6):435-9. doi: 10.1016/j.pediatrneurol.2009.06.003. [PubMed: 19931165].
  • 16. Verrotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51(2):268-73. doi: 10.1111/j.1528-1167.2009.02206.x. [PubMed: 19682024].
  • 17. Lippi G, Mattiuzzi C, Meschi T, Cervellin G, Borghi L. Homocysteine and migraine. A narrative review. Clin Chim Acta. 2014;433:5-11. doi: 10.1016/j.cca.2014.02.028. [PubMed: 24613517].
  • 18. Belcastro V, Striano P, Gorgone G, Costa C, Ciampa C, Caccamo D, et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia. 2010;51(2):274-9. doi: 10.1111/j.1528-1167.2009.02303.x. [PubMed: 19780797].
  • 19. Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F, et al. Migraine and risk of ischaemic heart disease: A systematic review and meta-analysis of observational studies. Eur J Neurol. 2015;22(6):1001-11. doi: 10.1111/ene.12701. [PubMed: 25808832].
  • 20. Sharpe C, Wolfson T, Trauner DA. Weight gain in children treated with valproate. J Child Neurol. 2009;24(3):338-41. doi: 10.1177/0883073808323023. [PubMed: 19258293].
  • 21. Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: Risk predictors of weight gain. Eur J Paediatr Neurol. 2009;13(3):261-8. doi: 10.1016/j.ejpn.2008.05.005. [PubMed: 18586538].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments